

Evgeny Arons

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2774374/publications.pdf>

Version: 2024-02-01

33
papers

940
citations

758635

12
h-index

525886

27
g-index

33
all docs

33
docs citations

33
times ranked

882
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | High prevalence of MAP2K1 mutations in variant and IGHV4-34â€œexpressing hairy-cell leukemias. <i>Nature Genetics</i> , 2014, 46, 8-10. | 9.4 | 236 |
| 2 | Both variant and IGHV4-34â€œexpressing hairy cell leukemia lack the BRAF V600E mutation. <i>Blood</i> , 2012, 119, 3330-3332. | 0.6 | 202 |
| 3 | VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. <i>Blood</i> , 2009, 114, 4687-4695. | 0.6 | 143 |
| 4 | Cladribine with Immediate Rituximab for the Treatment of Patients with Variant Hairy Cell Leukemia. <i>Clinical Cancer Research</i> , 2013, 19, 6873-6881. | 3.2 | 62 |
| 5 | Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 1527-1538. | 0.8 | 58 |
| 6 | Somatic hypermutation and VH gene usage in hairy cell leukaemia. <i>British Journal of Haematology</i> , 2006, 133, 504-512. | 1.2 | 35 |
| 7 | Minimal Residual Disease in Hairy Cell Leukemia Patients Assessed by Clone-Specific Polymerase Chain Reaction. <i>Clinical Cancer Research</i> , 2006, 12, 2804-2811. | 3.2 | 33 |
| 8 | Evidence of canonical somatic hypermutation in hairy cell leukemia. <i>Blood</i> , 2011, 117, 4844-4851. | 0.6 | 31 |
| 9 | Molecular variant of hairy cell leukemia with poor prognosis. <i>Leukemia and Lymphoma</i> , 2011, 52, 99-102. | 0.6 | 24 |
| 10 | Differential Expression of CD43, CD81, and CD200 in Classic Versus Variant Hairy Cell Leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 275-282. | 0.7 | 20 |
| 11 | Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 1100-1110. | 2.0 | 16 |
| 12 | Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome. <i>British Journal of Haematology</i> , 2014, 166, 729-738. | 1.2 | 13 |
| 13 | Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant. <i>Blood Advances</i> , 2021, 5, 4807-4816. | 2.5 | 13 |
| 14 | Impact of telomere length on survival in classic and variant hairy cell leukemia. <i>Leukemia Research</i> , 2015, 39, 1360-1366. | 0.4 | 8 |
| 15 | Immunoglobulin light chain repertoire in hairy cell leukemia. <i>Leukemia Research</i> , 2007, 31, 1231-1236. | 0.4 | 7 |
| 16 | PRAME expression in hairy cell leukemia. <i>Leukemia Research</i> , 2008, 32, 1400-1406. | 0.4 | 5 |
| 17 | Expression of the muscle-associated gene MYF6 in hairy cell leukemia. <i>PLoS ONE</i> , 2020, 15, e0227586. | 1.1 | 5 |
| 18 | Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Blocks Hairy Cell Leukemia (HCL) Survival, Proliferation, and BCR Signaling: A New Therapeutic Approach for HCL. <i>Blood</i> , 2012, 120, 1802-1802. | 0.6 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Randomized phase II study of cladribine with simultaneous or delayed rituximab in patients with untreated hairy cell leukemia.. Journal of Clinical Oncology, 2019, 37, 7003-7003. | 0.8 | 5 |
| 20 | Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues. Blood Reviews, 2022, 51, 100888. | 2.8 | 4 |
| 21 | Pharmacokinetic Analysis Of Response In Hairy Cell Leukemia Treated By Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox. Blood, 2013, 122, 2871-2871. | 0.6 | 4 |
| 22 | In search of genetic factors predisposing to familial hairy cell leukemia (HCL): exome-sequencing of four multiplex HCL pedigrees. Leukemia, 2020, 34, 1934-1938. | 3.3 | 3 |
| 23 | High Response Rate of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia Includes Eradication of Minimal Residual Disease: Potential Importance for Outcome. Blood, 2015, 126, 4161-4161. | 0.6 | 3 |
| 24 | Generation of antibody-based therapeutics targeting the idiotype of B-cell malignancies. Antibody Therapeutics, 2019, 2, 12-21. | 1.2 | 2 |
| 25 | Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant. Blood, 2019, 134, 1536-1536. | 0.6 | 1 |
| 26 | Resolution of Hairy Cell Leukemia Minimal Residual Disease by Both BRAF and Clone-Specific Real-Time Quantitative PCR (RQ-PCR) After Treatment with Moxetumomab Pasudotox.. Blood, 2012, 120, 2896-2896. | 0.6 | 1 |
| 27 | Moxetumomab pasudotox and minimal residual disease in hairy cell leukemia.. Journal of Clinical Oncology, 2015, 33, 7079-7079. | 0.8 | 1 |
| 28 | Phase 1 trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox combined with rituximab for relapsed/refractory hairy cell leukemia.. Journal of Clinical Oncology, 2021, 39, 7036-7036. | 0.8 | 0 |
| 29 | Interim Results of Secondary Endpoints From a Randomized Trial of Cladribine with Early Vs Delayed Rituximab for Treatment of Early Hairy Cell Leukemia. Blood, 2011, 118, 2856-2856. | 0.6 | 0 |
| 30 | Bendamustine and Rituximab for the Treatment of Multiply Relapsed Hairy Cell Leukemia,. Blood, 2011, 118, 3909-3909. | 0.6 | 0 |
| 31 | Presence and Absence of the BRAF V600E Mutation in Hairy Cell Leukemia and Its Variants. Blood, 2011, 118, 931-931. | 0.6 | 0 |
| 32 | Durability of complete remission by moxetumomab pasudotox (HA22 or CAT-8015) assessed by clone-specific real-time quantitative PCR (RQ-PCR).. Journal of Clinical Oncology, 2012, 30, 2503-2503. | 0.8 | 0 |
| 33 | The HLA-DRB1*11 Antigen Is Preferentially Expressed in Hairy Cell Leukemia, Particularly in Patients Who Had Hemolytic Uremic Syndrome with Recombinant Immunotoxin BL22.. Blood, 2012, 120, 2488-2488. | 0.6 | 0 |